ライフサイエンスコーパス: naproxen

1 dentical design (lumiracoxib vs ibuprofen or naproxen).

2 (e.g., cholesterol, estrone, ibuprofen, and naproxen).

3 Thus, SCC-25 cells possess transporters for naproxen.

4 h as hydroxylating the antiinflammatory drug naproxen.

5 ecoxib, celecoxib, parecoxib, valdecoxib and naproxen.

6 events compared with the nonselective NSAID naproxen.

7 s been interpreted as a protective effect of naproxen.

8 I: 1.07, 2.69) when comparing rofecoxib with naproxen.

9 00 mg/day or to begin placebo in addition to naproxen.

10 hanges in basal firing and was unaffected by naproxen.

11 mg twice per day, respectively; and 31 % for naproxen.

12 incidence of endoscopic ulcers compared with naproxen.

13 infection who had received azithromycin and naproxen.

14 macrophage efferocytosis, with comparison to naproxen.

15 nduced paw edema, as did indomethacin or (S)-naproxen.

16 d by celecoxib and weakened by diclofenac or naproxen.

17 NSAIDs such as ibuprofen, flurbiprofen, and naproxen.

18 assigned to receive celecoxib, ibuprofen, or naproxen.

19 te the evident macroscopic damage induced by naproxen.

20 with her rheumatoid arthritis and was taking naproxen.

21 nonsteroidal anti-inflammatory drug (NSAID) naproxen.

22 out 20x at little expense of the activity of naproxen.

23 for the development of pain and response to naproxen.

24 group (1.9%) (hazard ratio for celecoxib vs. naproxen, 0.90; 95% CI, 0.71 to 1.15; hazard ratio for c

25 group (2.7%) (hazard ratio for celecoxib vs. naproxen, 0.93; 95% confidence interval [CI], 0.76 to 1.

26 The remaining patients received naproxen 1,000 mg/day for 3 weeks.

27 ts with painful OA of the knee responding to naproxen 1,000 mg/day, the addition of tramadol 200 mg/d

28 mization was stratified based on response to naproxen 1,000 mg/day.

29 Naproxen (10 mg kg-1, I.V.), but not a cocktail of omega

30 Inhibition of cyclo-oxygenase with naproxen (10 microM) prevented sensitization after hista

31 ng blockade of cyclo-oxygenase activity with naproxen (10 microM).

32 low-dose aspirin increased event rates with naproxen 2-fold and etodolac 9-fold.

33 f 30 metabolites plus the therapeutic agent, naproxen (24/30), passed the t-test for the control-norm

34 king the nonsteroidal anti-inflammatory drug naproxen (3 cases) or acetaminophen (2 cases) but in who

35 n 400 mg (MDp, 1.31; 95% CI, 1.17-1.45), and naproxen 400-440 mg (MDp, 1.44; 95% CI, 1.07-1.80) were

36 mong the target compounds (63%), followed by naproxen (43%).

37 ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not si

38 values for endothelial cells vs. platelets: naproxen -5.59+/-0.07 vs. -4.81+/-0.04; rofecoxib -4.93+

39 bable membrane plus twice daily postsurgical naproxen 500 mg for one week (test or GPN group) or with

40 mg twice a day; rofecoxib 25 mg once a day; naproxen 500 mg twice a day; or placebo for 6 weeks.

41 d to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg

42 d to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg

43 andomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months.

44 1 year or greater were randomly assigned to naproxen 500 mg twice daily or rofecoxib 50 mg daily.

45 ed to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times

46 1-week medication washout were treated with naproxen 500 mg/day for 1 week.

47 Naproxen, 500 mg twice daily, and coxib, once daily.

48 eks, rofecoxib, 25 mg/d, was as effective as naproxen, 500 mg twice daily, but had statistically sign

49 Rofecoxib, 25 mg/d, or naproxen, 500 mg twice daily.

50 r day (n = 240, 235, and 218, respectively); naproxen, 500 mg twice per day (n = 225); or placebo (n

51 All participants were given 20 tablets of naproxen, 500 mg, to be taken twice a day.

52 One group received sodium naproxen 550 mg b.i.d. plus placebo for 7 days, while th

53 days, while the other group received sodium naproxen 550 mg b.i.d. plus rebamipide 100 mg b.i.d.

54 I endoscopy study, 19% of subjects receiving naproxen (6 of 32) developed gastric ulcers, whereas no

55 0.1-4.8 days), sulfamethoxazole (2-33 days), naproxen (6-19 days), carbamazepine (355-1,624 days), an

56 2 +/- 3% for sulfamethoxazole, 84 +/- 3% for naproxen, 82 +/- 3% for ibuprofen, 66 +/- 2% for carbama

57 acetaminophen (95% CI: 0.77, 1.03), 1.07 for naproxen (95% CI: 0.85, 1.35), and 1.05 for aspirin (95%

58 For example, after 120 h, the metabolites of naproxen accounted for >90% of the extractable chemical

59 ritis patients taking the nonselective NSAID naproxen, accounting for nearly 40% of the serious GI ev

60 Naproxen accumulation was more efficient at acidic pH th

61 pants randomized) received a prescription of naproxen, acetaminophen (paracetamol), and pantoprazole;

62 elated NSAIDs, niflumic acid, ibuprofen, and naproxen, acutely increase intracellular zinc stores fro

63 (adjusted OR 0.52; 95% CI: 0.39 to 0.69) and naproxen (adjusted OR 0.48; 95% CI: 0.28 to 0.82).

64 of a steroid derivative, oleyl alcohol, and naproxen alcohol were employed.

65 yclobenzaprine or oxycodone/acetaminophen to naproxen alone did not improve functional outcomes or pa

66 Naproxen also improved renal cloudy swelling, necrosis,

67 Naproxen also reduced overall pain incidence from 71.3%

68 g rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of plat

69 We examined a series of naproxen analogues and find that (R)-2-(6-methoxynaphtha

70 ationic thioflavin T, or the hydrophobic (S)-naproxen and (R)-ibuprofen molecules.

71 ent or lower GI event) among patients taking naproxen and 42.7% among those taking rofecoxib.

72 xtracellular concentration ratio was 1.9 for naproxen and 7.2 for ibuprofen.

73 Treatments more used to migraine, such as naproxen and a calcitonin gene-related peptide receptor

74 on between ibuprofen and aspirin and between naproxen and aspirin but not between celecoxib and aspir

75 ng were monitored during coincubation of (S)-naproxen and CYP2C9 over a range of P450 reductase conce

76 A selective response to naproxen and dexketoprofen with tolerance to ibuprofen w

77 sion of autophagic marker LC3 was reduced by naproxen and diclofenac, but not celecoxib.

78 A was observed in animals that received both naproxen and either Bay y 1015 or Bay x 1005.

79 idence of CSUGI events was .78% and .24% for naproxen and etodolac, respectively.

80 idence of CSUGI events was .99% and .24% for naproxen and etodolac, respectively.

81 Gram-scale synthesis of medication Naproxen and Flurbiprofen with low palladium loading fur

82 ddition, tert-butyl esters, such as those of Naproxen and Flurbiprofen, were prepared from tert-butyl

83 s and allosteric COX-2 inhibitors, including naproxen and flurbiprofen.

84 copy was performed for microcrystals of both naproxen and glucose isomerase.

85 these results, the binding properties toward naproxen and ibuprofen were measured for two combinatori

86 Naproxen and ibuprofen, in their parent form, were conju

87 Here, we evaluated the metabolism of naproxen and ibuprofen, two of the most-used human drugs

88 h two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen.

89 2-lowering agent (SALA), over the non-SALAs, naproxen and MF-tricyclic.

90 nd poor removal of 2-APAs (<=30%, except for naproxen) and diverse chiral inversion behaviors under a

91 (acetaminophen, diazepam, methylparaben, and naproxen) and their methylated or demethylated TPs in Ar

92 tive agents with cox-2>cox-1 inhibition (eg, naproxen), and nonselective agents with cox-1>cox-2 inhi

93 ctional inversion [flurbiprofen, ketoprofen, naproxen, and 2-(4-tert-butylphenyl)propionic acid], and

94 reatment of migraine, including sumatriptan, naproxen, and a calcitonin gene-related peptide antagoni

95 oral formulations of diclofenac, ibuprofen, naproxen, and a composite of all other NSAIDs.

96 The non-selective NSAIDs, ibuprofen and naproxen, and a selective COX-2 inhibitor, MF-tricyclic,

97 mmatory drugs including ibuprofen, fenbupen, naproxen, and acetaminophen also up-regulated ACOX::CAT.

98 l C-H oxidation methods using oxcarbazepine, naproxen, and an early compound hit (phthalazine 1).

99 Although ibuprofen, naproxen, and celecoxib all had the potential to compete

100 nsity of commonly consumed NSAIDs-ibuprofen, naproxen, and celecoxib-to cause a drug-drug interaction

101 ies for the mu-EME of ibuprofen, ketoprofen, naproxen, and diclofenac exceed 40% in real samples.

102 orption and release conditions of ibuprofen, naproxen, and diclofenac using a theoretical and experim

103 ory drugs (NSAIDs) (indomethacin, ibuprofen, naproxen, and flurbiprofen).

104 nsteroidal antiinflammatory drugs ibuprofen, naproxen, and flurbiprofen.

105 and roach living in a lake where diclofenac, naproxen, and ibuprofen are present as pollutants.

106 observed bile concentrations of diclofenac, naproxen, and ibuprofen in bream ranged from 6 to 95 ng

107 thoxazole, carbamazepine, tylosin, atrazine, naproxen, and ibuprofen) by intentionally stimulating th

108 cyclooxygenase inhibitors such as ibuprofen, naproxen, and indomethacin were used as orally bioavaila

109 * have been determined by energy transfer to naproxen, and it has been found that its energy is lower

110 rbiprofen, ibuprofen, oxaprozin, fenoprofen, naproxen, and ketoprofen.

111 teroidal anti-inflammatory drugs: ibuprofen, naproxen, and ketoprofen.

112 trin with benzene, resorcinol, flurbiprofen, naproxen, and nabumetone.

113 arated a standard mixture of 1 mM ibuprofen, naproxen, and phenylbutazone using a commercially availa

114 a40 aggregation inhibitor than ibuprofen and naproxen, and prevented Abeta42 oligomer formation and t

115 The oxidation products of methylene blue, naproxen, and sulfamethoxazole by PAA-Fe(III)-PICA were

116 ation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L)

117 usly been implicated, ibuprofen, nabumetone, naproxen, and tolmetin were found to be associated.

118 e, primidone, DEET, carbamazepine, dilantin, naproxen, and triclosan.

119 f a variety of drugs, including propranolol, naproxen, and warfarin.

120 pride, flufenamic acid, hydrochlorothiazide, naproxen, and xipamide can be quantitatively explained b

121 Differences observed between rofecoxib and naproxen are likely the result of the antiplatelet effec

122 acking interactions between two molecules of naproxen are necessary for binding in a catalytically fa

123 The results show that Ibuprofen and Naproxen are the most soluble and insoluble drugs in SCC

124 nflammatory properties in humans compared to naproxen are yet to be confirmed.

125 bservations reveals potential limitations of naproxen as an effective therapeutic agent in the treatm

126 The RD for naproxen as well as its upper 95% CI was the lowest of a

127 active ingredient (ibuprofen, acetaminophen, naproxen, aspirin) and cumulative monthly dose.

128 -controlled clinical trial demonstrated that naproxen at a dose of 500 mg twice per day is effective

129 In humans, systemically administered naproxen attained steady-state levels of 61.9 mug/mL in

130 l biosensor for the continuous monitoring of Naproxen based on cytochrome P450.

131 The analysis of naproxen binding energetics shows that the location of l

132 ammatory drugs (e.g. aspirin, ibuprofen, and naproxen) block PG synthesis by inhibiting COX-1 and COX

133 ed for inline chiral derivatization with (S)-naproxen chloride and subsequent preseparation.

134 , TXA2) were all more effectively reduced by naproxen compared with celecoxib or diclofenac.

135 NSAID (rofecoxib, diclofenac, ibuprofen, and naproxen compared with celecoxib) therapy was assessed u

136 The anti-inflammatory drug naproxen could be detected in all the six bream and roac

137 The MEND was defined as 250 mg above the naproxen daily dosage at which pain relief was no longer

138 ination of five pharmaceutical contaminants (naproxen, danofloxacin, ofloxacin, sarafloxacin, and eno

139 In contrast to flurbiprofen and naproxen, dapsone did not activate the 4'-hydroxylation

140 Patients were stabilized with 1,000 mg naproxen/day and then began a 6-week, double-blind trial

141 out whether high-dose rofecoxib increases or naproxen decreases the risk of serious coronary heart di

142 iants are associated with lower rates of (S)-naproxen demethylation.

143 d the effects of naproxcinod, an NO-donating naproxen derivative, on the skeletal and cardiac disease

144 Thus, the antioxidant-naproxen derivatives represent a novel series of agents

145 The microbial cleavage of ibuprofen, naproxen, diclofenac, and mecoprop was confirmed for all

146 Inhibitors of COX (naproxen, diclofenac, or ibuprofen) increased bronchocon

147 of salicylic acid, bisphenol A, gemfibrozil, naproxen, diclofenac, technical 4-nonylphenol, and 4-ter

148 n-steroidal anti-inflammatory drugs, such as naproxen, dicofenac and ibuprofen, might differ in their

149 For example, naproxen directly and completely inhibits COX-1 by bindi

150 ibrate, irbesartan, valsartan, ibuprofen and naproxen displayed lower half-lives at shorter flowpaths

151 In contrast, the non-RhoA-inhibiting NSAID naproxen does not have the axon growth-promoting effects

152 is study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients wit

153 ers and nonresponders react to a decrease in naproxen dosage after the addition of tramadol.

154 efficacy end point was the minimum effective naproxen dose (MEND).

155 icacy were assigned a MEND equal to the last naproxen dose received.

156 During the double-blind phase, the naproxen dose was reduced by 250 mg every 2 weeks.

157 ts (5596 patient-years) received etodolac or naproxen during a 3-year period without concurrent use o

158 Notably, they successfully separated racemic naproxen enantiomers, achieving enantiomeric excess (ee)

159 luronic F-127, and glucosylceramide enhanced naproxen entry.

160 Compared with naproxen, etodolac was associated with a reduction in up

161 The administration of postsurgical naproxen failed to produce osseous healing that was stat

162 can produce metabolites of acetaminophen and naproxen for which certain drug-dependent antibodies are

163 rsification of the derivatives of ibuprofen, naproxen, gemfibrozil, helional, and amino acids.

164 in the presence of a known drug metabolite (naproxen glucuronide or acetaminophen sulfate) were iden

165 celecoxib group (1.7%), 144 patients in the naproxen group (1.8%), and 155 patients in the ibuprofen

166 celecoxib group (2.3%), 201 patients in the naproxen group (2.5%), and 218 patients in the ibuprofen

167 tly lower in the rofecoxib group than in the naproxen group (5.9% vs. 8.1%; relative risk, 0.74 [95%

168 (mean [+/-SD] daily dose, 209+/-37 mg), the naproxen group (852+/-103 mg), or the ibuprofen group (2

169 7.71 for the placebo group and 6.04 for the naproxen group (P = .037).

170 was the CSUGI event rate of the etodolac and naproxen groups without concomitant low-dose aspirin.

171 Naproxen had an average market share of less than 10%.

172 prostaglandin E2 (PGE2), in the presence of naproxen, had no direct effect on afferent activity, but

173 Similarly, the cyclooxygenase inhibitor, naproxen, had no effect on the ischaemic afferent respon

174 pirin, ibuprofen, diclofenac, ketoprofen and naproxen have been touched.

175 acute myocardial infarction, and studies of naproxen have found a possible protective effect.

176 the covalent conjugation of d-amino acids to naproxen (i.e., a NSAID) not only affords supramolecular

177 s with documented harmful effects, including naproxen, ibuprofen and rubella live vaccine.

178 Rate ratios for naproxen, ibuprofen, and other NANSAIDs were 0.95 (0.82-

179 SAIDs (nonsteroidal anti-inflammatory drugs) naproxen, ibuprofen, flurbiprofen, ketoprofen, and fenop

180 of many drug analogues such as pirfenidone, naproxen, ibuprofen, geraniol, umbelliferone, pregnenolo

181 and the nonspecific COX inhibitors, aspirin, naproxen, ibuprofen, or indomethacin.

182 that cultured gingival fibroblasts transport naproxen in a saturable, temperature-dependent manner wi

183 ATB-346 was non-inferior to naproxen in terms of its inhibition of cyclooxygenase ac

184 between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events.

185 lating anti-inflammatory agents (aspirin and naproxen) in these polymeric nanomicelles and by applyin

186 , acetaminophen, and other NSAID (ibuprofen, naproxen, indomethacin) use were based on a self-adminis

187 spirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumi

188 spirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumi

189 Sodium naproxen induced gastric damage in both groups.

190 udy evaluated if rebamipide protects against naproxen-induced gastric damage in healthy volunteers.

191 Rebamipide does not protect against naproxen-induced gastric damage in healthy volunteers.

192 As a result naproxen induces a destabilizing effect on Abeta dimer.

193 By comparing the free-energy landscapes of naproxen interactions with Abeta dimers and fibrils, we

194 between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use.

195 We show that naproxen ligands bind to Abeta dimer and penetrate its v

196 that the nonsteroidal antiinflammatory drug naproxen may be useful in the treatment of Alzheimer's d

197 d that other nonselective agents, especially naproxen, may provide some lesser degree of cardioprotec

198 rapid, reversible COX inhibitors (ibuprofen, naproxen, mefenamic acid, and lumiracoxib) demonstrated

199 Naphthalene metabolism by CYP3A4 and naproxen metabolism by CYP2C9 demonstrated nonhyperbolic

200 4 and dapsone activation of flurbiprofen and naproxen metabolism by CYP2C9 were also observed.

201 y drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-ind

202 e proposed biosensor was employed to monitor Naproxen (NAP), a well-known anti-inflammatory compound,

203 xidize pharmaceuticals (carbamazepine (CBZ), naproxen (NAP), trimethoprim (TMP), and sulfonamide anti

204 uprofen, Ketoprofen, Loxoprofen, Nabumetone, Naproxen, Nimesulide, Phenylbutazone, Piroxicam, Salicyl

205 For the naproxen nonresponders, the mean MEND was 419 mg in the

206 stratified as naproxen responders and 146 as naproxen nonresponders.

207 ays confirmed that AK transforms galaxolide, naproxen, nonylphenol, octylphenol, ibuprofen, diclofena

208 mmatory drugs (NSAIDs), diclofenac (Dic) and naproxen (Nps), were studied by X-ray crystallography an

209 The nonsteroidal anti-inflammatory drug naproxen (NPX) is among the most consumed pharmaceutical

210 ecoxib relative to either placebo or the non-naproxen NSAIDs that were studied.

211 .40, 1.55) when comparing rofecoxib with non-naproxen NSAIDs; and 1.69 (95% CI: 1.07, 2.69) when comp

212 alyzed S-flurbiprofen 4'-hydroxylation and S-naproxen O-demethylation by dapsone.

213 NSAIDs were the following: rofecoxib versus naproxen (odds ratio, 3.39 [CI, 1.37 to 8.40]) and celec

214 Diclofenac was listed on 74 national EMLs, naproxen on just 27.

215 effect of a one week course of postsurgical naproxen on the osseous healing in intrabony defects.

216 o measure the effects of NANSAIDs, including naproxen, on risk of serious coronary heart disease.

217 inhibition (HR, 1.17; 1.10-1.24; P<0.001 and naproxen only: HR, 1.22; 1.12-1.34; P<0.001).

218 Prophylaxis against gout flares with naproxen or colchicine was provided during weeks 1 throu

219 Absence of a protective effect of naproxen or other NANSAIDs on risk of coronary heart dis

220 ine, the nonsteroidal anti-inflammatory drug naproxen or the steroidal antiinflammatory drug dexameth

221 ibuprofen (OR = 0.41, 95% CI: 0.2, 0.8), and naproxen/other NSAIDs (OR = 0.34, 95% CI: 0.1, 0.8).

222 The data suggests superior effect for naproxen over other NSAIDs in rectifying preeclamptic re

223 the catalytic efficiency of flurbiprofen and naproxen oxidation by 2.3- and 16.5-fold, respectively.

224 Phe114 and Phe476 abrogated flurbiprofen and naproxen oxidation, and MDS and kinetic studies with the

225 erall effect size for NSAIDs (P = 0.007) and naproxen (P = 0.04) groups based on data available from

226 significantly lower with celecoxib than with naproxen (P=0.01) or ibuprofen (P=0.002); the risk of re

227 significantly lower with celecoxib than with naproxen (P=0.19).

228 ile inverse to that of a weakly acidic drug (naproxen; pK(a) = 4.15).

229 ty acids (FAs) and some COX inhibitors (e.g. naproxen) preferentially bind to the COX site of E(allo)

230 Naproxen produced a moderate attenuation of carrageenan

231 Naproxen reduced maximum pain from 3.40 to 2.59 (P = .00

232 nt-years was 0.41 for rofecoxib and 0.89 for naproxen (relative risk, 0.46; 95% confidence interval [

233 1 years; 147 females), 90 were stratified as naproxen responders and 146 as naproxen nonresponders.

234 = 0.040) in the treatment effect between the naproxen responders and nonresponders, thus demonstratin

235 Among naproxen responders, the MEND was significantly lower in

236 The potencies of diclofenac, naproxen, rofecoxib, and salicylate, but not aspirin, ce

237 fenac, indomethacin, lumiracoxib, meloxicam, naproxen, rofecoxib, sodium salicylate, and SC560 as inh

238 and a significant reduction in the rate for naproxen (RR 0.75, 95% CI 0.62-0.92).

239 erval [95% CI] 1.14, 1.30) and decreased for naproxen (RR 0.79, 95% CI 0.67, 0.93).

240 affording chiral carboxylic acids including Naproxen, (S)-Flurbiprofen, and a d-DOPA precursor.

241 Comparison of the NANSAID rofexocib with naproxen showed a substantial difference in acute myocar

242 All dosages of celecoxib and naproxen significantly improved the signs and symptoms o

243 dontal treatment (scaling, root planing) and naproxen sodium (275 mg) administration daily for 6 week

244 ponse for the comparison between sumatriptan-naproxen sodium and each monotherapy.

245 of nausea did not differ between sumatriptan-naproxen sodium and placebo (65% vs 64%; P = .71).

246 ausea for the comparison between sumatriptan-naproxen sodium and placebo, and the percentages of pati

247 verse events was similar between sumatriptan-naproxen sodium and sumatriptan monotherapy.

248 onotherapy (16% and 14% in studies 1 and 2), naproxen sodium monotherapy (10% and 10% in studies 1 an

249 onducted to determine the possible effect of naproxen sodium on clinical status and the enzymatic pro

250 nd divided into two groups to receive either naproxen sodium or placebo.

251 tablet containing sumatriptan succinate and naproxen sodium relative to efficacy and safety of each

252 urs after dosing was higher with sumatriptan-naproxen sodium than placebo in study 1 (71% vs 65%; P =

253 Sumatriptan-naproxen sodium was more effective than placebo for head

254 ur sustained pain-free response, sumatriptan-naproxen sodium was superior at P<.01 (25% and 23% in st

255 Once-daily rofecoxib, 25 mg, or twice-daily naproxen sodium, 220 mg, or placebo.

256 m, 500 mg; sumatriptan, 85 mg (monotherapy); naproxen sodium, 500 mg (monotherapy); or placebo, to be

257 Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute tr

258 le tablet containing sumatriptan, 85 mg, and naproxen sodium, 500 mg; sumatriptan, 85 mg (monotherapy

259 s of commercially available APIs: piroxicam, naproxen sodium, and benzocaine.

260 flammatory drugs (NSAIDs) such as ibuprofen, naproxen sodium, etodolac, diclofenac, and ketorolac in

261 reatment except placebo was given instead of naproxen sodium.

262 In the naproxen substudy, rates of myocardial infarction (clini

263 lofenac, gemfibrozil, ibuprofen, ketoprofen, naproxen, sulfamethoxazole, and sildenafil).

264 es various MPs (methylene blue, bisphenol A, naproxen, sulfamethoxazole, carbamazepine, and trimethop

265 arious micropollutants (MPs: methylene blue, naproxen, sulfamethoxazole, carbamazepine, trimethoprim,

266 th lumiracoxib (18 events) versus 0.21% with naproxen (ten) and 0.11% with lumiracoxib (five) versus

267 iinflammatory drug derivatives such as (+/-)-naproxen tert-butyl ester and (+/-)-flurbiprofen tert-bu

268 er needed to treat with rofecoxib instead of naproxen to avert 1 GI event was 10-12 in highest risk p

269 s readily attached to common NSAIDs, such as naproxen, to generate YZ-597 as an efficient H(2)S-NSAID

270 al fraction of acids (diclofenac, genistein, naproxen, torasemide, and warfarin) and bases (metoprolo

271 Naproxen transport was most efficient at neutral pH and

272 ointestinal (GI) system, with the background naproxen treatment possibly contributing.

273 Combination of FSP vaccination with daily naproxen treatment potentiated immune response, delayed

274 Power analysis to determine superiority of naproxen treatment showed that a 12 per group sample siz

275 Naproxen use does not protect against serious coronary h

276 sers of rofecoxib, and a decreased rate with naproxen use.

277 ntiinflammatory drugs aspirin, ibuprofen and naproxen, used as positive controls in the assay at 108,

278 erence between the risk of toxicity with OTC naproxen versus OTC ibuprofen (adjusted OR, 0.84; 95% CI

279 The effect sizes for NSAIDs or naproxen versus placebo, as determined using data from r

280 For naproxen versus remote NSAID use the adjusted odds ratio

281 acks) with rofecoxib treatment compared with naproxen was 2.38 (95% confidence interval, 1.39-4.00; P

282 In contrast, the incidence with naproxen was 36 (26%) of 137, significantly greater than

283 olymeric nanomicelles containing aspirin and naproxen was 62 and 64%, respectively.

284 Naproxen was associated with a low risk.

285 es of the nonsteroidal antiinflammatory drug naproxen was designed to have both antiinflammatory and

286 When naproxen was directly compared with ibuprofen, the curre

287 ng this unbiased scanning method except that naproxen was not detected due to low sensitivity at nega

288 utanoic acid (in which the methyl group of R-naproxen was replaced by an ethyl group) acts as a poten

289 inhibitors (flufenamic acid, ibuprofen, and naproxen) was also readily evaluated.

290 1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were significant reduced by t-butylOOH.

291 Patients intolerant of naproxen were switched to a coxib.

292 onsteroidal antiinflammatory drugs [NSAIDs], naproxen) were determined by the mean changes from basel

293 Bay x 1005, and the cyclooxygenase inhibitor naproxen, were evaluated individually and in combination

294 ointestinal event rates between etodolac and naproxen when low-dose aspirin was taken concomitantly.

295 nflammatory drug (H(2) S-NSAID) derived from naproxen, which in preclinical studies has been shown to

296 Patients administered naproxen who had prior upper GI complications or who wer

297 trated that SCC-25 cell monolayers transport naproxen with a Michaelis constant (K(m)) and maximum ve

298 To investigate the interactions of naproxen with Abeta dimers, which are the smallest cytot

299 was found to be noninferior to ibuprofen or naproxen with regard to cardiovascular safety.

300 ows a significant reduction in the dosage of naproxen without compromising pain relief.